Form 8-K - Biogen Idec, Inc.
Table of Contents

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 17, 2005

Biogen Idec Inc.

(Exact name of registrant as specified in its charter)
         
Delaware   0-19311   33-0112644
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)
         
14 Cambridge Center, Cambridge, Massachusetts
  02142
(Address of principal executive offices)
  (Zip Code)

Registrant’s telephone number, including area code: (617) 679-2000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 8.01 Other Events
Item 9.01 Financial Statements and Exhibits
SIGNATURES
EXHIBIT INDEX
EX-99.1 - Press Release dated February 17, 2005


Table of Contents

Item 8.01 Other Events

     On February 17, 2005, the Registrant publicly disseminated a press release announcing that the Phase 3 TYSABRI® (natalizumab) AFFIRM monotherapy study achieved the two-year primary endpoint of slowing the progression of disability in patients with relapsing forms of multiple sclerosis and that the rate of clinical relapses, the study’s primary endpoint at one-year, was sustained over two years and consistent with previously reported one-year results. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

(c)   Exhibits.

  99.1   The Registrant’s Press Release dated February 17, 2005.

 


Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
  Biogen Idec Inc.
 
 
  By:   /s/ Anne Marie Cook    
    Anne Marie Cook   
    Vice President, Chief Corporate Counsel   
 

Date: February 22, 2005

 


Table of Contents

EXHIBIT INDEX

     
Exhibit Number   Description
99.1
  The Registrant’s Press Release dated February 17, 2005